Precipio Achieves Milestone Year: Transitioning to Self-Sustaining Business with Positive Cash Flow
In a major milestone for the company, Precipio has achieved an important objective, transitioning from a cash-using entity to a self-sustaining business with positive cash flow. This significant inflection point was reported by Ilan Danieli, CEO of Precipio, during the company's Q4 2025 and year-end shareholder update conference call.
As highlighted by Mr. Danieli, 2025 was a year of financial and strategic inflection for Precipio. The company achieved several other important milestones, including continued revenue growth, improved gross margin, and operational leverage. Additionally, all remaining financial warrants were exercised, removing any related overhang, and the repayment of the Change Healthcare loan was completed, allowing the company to move towards a clean balance sheet.
For many years, like most emerging diagnostic companies, Precipio had to manage its business with the constant constraint of conserving capital and extending its runway. This discipline has shaped the company into the highly efficient organization it is today, but also meant that decisions had to be made with short-term capital preservation in mind.
However, as highlighted by Mr. Danieli, Precipio enters a new phase of development, where resources can now be deployed towards growth initiatives and long-term value creation. The company's focus has shifted from stabilization to one centered on growth and execution.
The financial results for the year were also impressive, with Precipio delivering $24 million in revenue, representing a 30% increase year-over-year compared to 2024. This level of growth reflects the continued expansion primarily in its Pathology Services division, as well as strengthening demand for its specialized cancer diagnostic services and molecular testing technologies.
The company's business model has also demonstrated operational leverage, with a large portion of its cost structure already in place as fixed costs. As a result, incremental revenue can be absorbed efficiently without requiring proportional increases in operation costs.
According to Mr. Danieli, behind every diagnostic test run by Precipio is a patient waiting for answers, often during one of the most difficult moments of their lives. The company's tests help physicians determine the most appropriate treatment options for their patients battling cancer, and these answers must be provided quickly and accurately.
The financial results represent something beyond dollars and cents, according to Mr. Danieli. They represent Precipio's contribution to helping patients with cancer navigate their battle against the disease. The company's work has a direct impact on patients every day, and its performance in 2025 reflects this commitment to making a positive difference in people's lives.
